Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir versus lopinavir/ritonavir in second-line HIV-1 treatment
RBR-3m6cnyPhase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Jul 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in human immunodeficiency virus infection (HIV) comparing Dolutegravir + 2 NRTIs with Lopinavir/ritonavir + 2 NRTIs (2 arms). Started Jul 2015; status: completed.
02
Drugs
dolutegravirlopinavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on RBR-3m6cny.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-3m6cny.